<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787097</url>
  </required_header>
  <id_info>
    <org_study_id>D589BC00004</org_study_id>
    <secondary_id>2010-020440-35</secondary_id>
    <nct_id>NCT01787097</nct_id>
  </id_info>
  <brief_title>Effect of Symbicort ® on GR in Sputum in COPD</brief_title>
  <official_title>GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research (or &quot;knowledge gap&quot; this research is designed to fill) is to&#xD;
      understand the science of how the combination therapy of 2 drugs (inhaled longacting&#xD;
      beta-agonists(LABA) and inhaled corticosteroids (ICS), which are commonly used in chronic&#xD;
      obstructive pulmonary disease (COPD) patients, is better than each drug alone. ICS and LABA&#xD;
      both have antiinflammatory properties; that is, they dampen the inflammation in the cells of&#xD;
      the airways in the lungs. The combination of LABA and ICS has also been shown to improve&#xD;
      clinical effectiveness in asthma patients. The addition of a LABA to LOW doses of ICS has&#xD;
      been shown to be more clinically beneficial in asthma than the use of HIGH doses of ICS&#xD;
      alone. This has allowed a reduction in the total ICS dose and minimised the adverse side&#xD;
      effects of inhaled corticosteroids. Recent evidence suggests that the use of combination&#xD;
      therapy of LABA and ICS may also improve clinical effectiveness in COPD patients.&#xD;
&#xD;
      Investigators will address this hypothesis by examining the inflammation cells of COPD direct&#xD;
      from the site of disease (the airways) by looking at sputum/mucus. This research will build&#xD;
      on the existing knowledge of the science of how these drugs work in asthma and COPD and&#xD;
      allows us to understand the molecular science, which may support new future drug targets for&#xD;
      patients with COPD, which are greatly needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corticosteroids exert their effects by binding to a cytoplasmic glucocorticoid receptor (GR).&#xD;
      The inactive GR is bound to a protein complex that includes heat shock protein hsp90, acting&#xD;
      as molecular chaperones to prevent the nuclear localisation of unoccupied GR.&#xD;
&#xD;
      GR binding to the palindromic promotor induces the transcriptional induction of&#xD;
      anti-inflammatory genes such as mitogen-activated protein kinase phosphatase-1 (MKP-1) and&#xD;
      secretory leukocyte protease inhibitor (SLPI). GR-steroid complex also binds to negative GRE&#xD;
      sequences, resulting in inhibition of pro-inflammatory mediators, such as IL-6. More&#xD;
      importantly, GR binds transcription factor with recruitment of histone deacetylase (HDAC) and&#xD;
      inhibits wide range of pro-inflammatory cytokines. By this process of transrepression,&#xD;
      corticosteroids reduce such pro-inflammatory cytokines as tumour necrosis-alpha (TNF-alpha)&#xD;
      and interleukin-8 (IL-8) in asthmatic patients whereas they are far less effective in chronic&#xD;
      obstructive pulmonary disease (COPD) patients.&#xD;
&#xD;
      The combination of inhaled corticosteroids (ICS) and long acting beta 2-agonists (LABAs) has&#xD;
      been shown to improve clinical effectiveness and anti-inflammatory properties in asthma. The&#xD;
      addition of a LABA to low dose ICS has been shown to be more clinically beneficial in asthma&#xD;
      than the use of high dose ICS, allowing a reduction in ICS dose and minimising and adverse&#xD;
      side effects of corticosteroids. Recent evidence suggests that this may also be the case in&#xD;
      COPD.&#xD;
&#xD;
      ICS such as budesonide, beclomethasone and fluticasone have been used in combination with&#xD;
      LABA's such as formoterol and salmeterol. These combination treatments are established in&#xD;
      national guidelines for treating patients with asthma and also, COPD. The combination of&#xD;
      formoterol and budesonide (Symbicort ®, Astra Zeneca) will be studied in this project.&#xD;
&#xD;
      Evidence suggests that LABAs enhance GR function in vitro. In an asthmatics study, the&#xD;
      combination of formoterol and budesonide (Symbicort ®, Astra Zeneca) was as effective as high&#xD;
      dose ICS on GR activation, gene transactivation and transrepression. However, the precise&#xD;
      mechanisms for this enhanced effectiveness are unknown, although priming of the steroid&#xD;
      receptor (GR) by LABAs may be important.&#xD;
&#xD;
      Investigators have developed a novel method of measuring GR-GRE binding activity in sputum&#xD;
      using an enzyme immunosorbent assay system. This method, together with the measurements of&#xD;
      some functional readouts, will help us to understand some of the mechanisms of steroid and GR&#xD;
      interactions using non-invasive methods of assessment of the airways. This may provide&#xD;
      insight into the mechanisms of corticosteroid action and whether the addition of a LABA to&#xD;
      ICS can alter molecular patterns, which may explain the observed beneficial action of&#xD;
      combination therapy seen in patient studies in vivo. This may allow a scientific basis to&#xD;
      explore future drug interactions that may be helpful in patients, particularly those patients&#xD;
      whose disease tends to be severe and may be unresponsive to standard therapies for COPD&#xD;
      and/or where high dose ICS have little beneficial clinical effect and have led to&#xD;
      side-effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GR-GRE Binding (Relative to Baseline)</measure>
    <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
    <description>Enzyme immunosorbent assay system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in IL-6 Levels</measure>
    <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
    <description>Changes in IL-6 Levels in the sputum supernatant compared to screening visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CXCL8 Levels</measure>
    <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
    <description>Changes in CXCL8 concentrations in sputum compared to screening visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in TNF Alpha</measure>
    <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
    <description>Sputum TNF-alpha levels obtained from induced sputum compared to screening visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lung Function Parameter FEV1</measure>
    <time_frame>Baseline and 2 hours post inhalation</time_frame>
    <description>Improvement in FEV1 compared to baseline levels.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Obstructive Lung Disease</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with COPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort® total dose 400ug/12ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort® total dose 800ug/24ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUD total dose 800ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BUD total dose 800ug: is an intermediate dose of ICS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® total dose 400ug/12ug</intervention_name>
    <description>Symbicort® is combination of formoterol 400ug and budesonide 12ug. Single dose</description>
    <arm_group_label>Symbicort® total dose 400ug/12ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® total dose 800ug/24ug</intervention_name>
    <description>Symbicort® is combination of formoterol 800ug and budesonide 24ug. Single dose</description>
    <arm_group_label>Symbicort® total dose 800ug/24ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 24ug</intervention_name>
    <description>Turbuhaler</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUD total dose 800ug</intervention_name>
    <description>Turbuhaler</description>
    <arm_group_label>BUD total dose 800ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (n=30) with chronic obstructive pulmonary disease (COPD) with&#xD;
             mild-to-moderate disease severity (GOLD 1 and 2 guidelines). The post-bronchodilator&#xD;
             FEV1 will be used in the criteria to define GOLD severity (reference 7/Table 1).&#xD;
&#xD;
          2. Aged 38-80 years inclusive&#xD;
&#xD;
          3. FEV1 &lt;15% reversibility (not % predicted) and/or an increase of &lt;200 ml after inhaled&#xD;
             β2-agonists (400 μg salbutamol)&#xD;
&#xD;
          4. Patients will be allowed to use their current short-acting β2-agonists (SABA) and&#xD;
             long-acting β2-agonists (LABA) and short-acting muscarinic-antagonist (SAMA) and&#xD;
             long-acting muscarinic-antagonists (LAMA). However they should refrain from&#xD;
             short-acting β2-agonists (SABA) and short-acting muscarinic-antagonist (SAMA) for 6&#xD;
             hours before the study visit and for long-acting β2-agonists (LABA) and long-acting&#xD;
             muscarinic-antagonists (LAMA) at least 12 hours before the study visit, unless needed&#xD;
             by the patient's clinical condition.&#xD;
&#xD;
          5. Theophylline (an oral tablet bronchodilator) will be required to be stopped at least 3&#xD;
             days prior to start of Study Visit one, and patients will not be allowed this&#xD;
             treatment during the study as it may affect the GR response and the bronchodilator&#xD;
             (lung function, spirometry) responses.&#xD;
&#xD;
          6. Capable of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. As a result of the medical interview, physical examination or screening&#xD;
             investigations, the Physician Responsible considers the volunteer unfit for the study.&#xD;
&#xD;
          2. Patients who have a clinical diagnosis of Asthma, as decided by the Study&#xD;
             Investigators, as this does not fulfil the diagnosis of chronic obstructive pulmonary&#xD;
             disease (COPD).&#xD;
&#xD;
          3. Patients who have had a history of an upper or lower respiratory infection (including&#xD;
             sinusitis) within 4 weeks prior to study entry, as this can affect the breathing&#xD;
             response.&#xD;
&#xD;
          4. Patients who have received oral or parenteral steroids within 4 weeks prior to study&#xD;
             entry, as this can affect the breathing response and signifies that their condition&#xD;
             needs to be controlled better.&#xD;
&#xD;
          5. Patients who have been hospitalised for a COPD exacerbation within 1 month of study&#xD;
             entry and/or has received antibiotics within 4 weeks of study entry, as this signifies&#xD;
             that their condition needs to be controlled better.&#xD;
&#xD;
          6. Patients taking any regular medication that is contraindicated (as indicated in the&#xD;
             British National Formulary) in those about to receive the study medications listed in&#xD;
             this protocol; other than the oral contraceptive pill.&#xD;
&#xD;
          7. Any evidence of a positive pregnancy urine test for female volunteers or females who&#xD;
             are pregnant or lactating or are likely to become pregnant during the trial. Women of&#xD;
             child-bearing potential may be included in the study if, in the opinion of the&#xD;
             investigator, they are taking adequate contraceptive precautions (which will be&#xD;
             directly enquired at the screening visit).&#xD;
&#xD;
          8. Patients who have a history of drug allergy which, in the opinion of the Unit&#xD;
             Physician, contraindicates his/her participation in the study.&#xD;
&#xD;
          9. Patients with a known or suspected allergy to corticosteroids or any component of the&#xD;
             formulations and/or suspected hypersensitivity to inhaled corticosteroid (this will be&#xD;
             asked directly at the screening visit).&#xD;
&#xD;
         10. Patients who regularly, or on average, drink more than 21 units of alcohol (males) and&#xD;
             14 units of alcohol (female) per week (this will be asked directly at the screening&#xD;
             visit).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar S Usmani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000 Sep;20(18):6891-903.</citation>
    <PMID>10958685</PMID>
  </reference>
  <reference>
    <citation>Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542-8.</citation>
    <PMID>9032192</PMID>
  </reference>
  <reference>
    <citation>Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1635-9.</citation>
    <PMID>10556133</PMID>
  </reference>
  <reference>
    <citation>Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449-56. Erratum in: Lancet. 2003 May 10;361(9369):1660.</citation>
    <PMID>12583942</PMID>
  </reference>
  <reference>
    <citation>Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003 Dec;22(6):912-9. Erratum in: Eur Respir J. 2004 Dec;24(6):1075.</citation>
    <PMID>14680078</PMID>
  </reference>
  <reference>
    <citation>Essilfie-Quaye S, Ito K, Ito M, Kharitonov SA, Barnes PJ. Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients. Respir Med. 2011 Dec;105(12):1784-9. doi: 10.1016/j.rmed.2011.08.020. Epub 2011 Sep 7.</citation>
    <PMID>21903370</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <results_first_submitted>February 23, 2016</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Lung Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant was enrolled January 2013. 4 participants withdrew before randomisation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Formoterol 24ug</title>
          <description>The first intervention is Formoterol (FORM) total dose 24ug, then Symbicort® total dose 400ug/12ug, then Symbicort® total dose 800ug/24ug, then BUD total dose 800ug</description>
        </group>
        <group group_id="P2">
          <title>Symbicort® Total Dose 400ug/12ug</title>
          <description>The first intervention is Symbicort® total dose 400ug/12ug, then Formoterol (FORM) total dose 24ug, then Symbicort® total dose 800ug/24ug, then BUD total dose 800ug</description>
        </group>
        <group group_id="P3">
          <title>Symbicort® Total Dose 800ug/24ug</title>
          <description>The first intervention is Symbicort® total dose 800ug/24ug, then Formoterol (FORM) total dose 24ug, then Symbicort® total dose 400ug/12ug, then BUD total dose 800ug</description>
        </group>
        <group group_id="P4">
          <title>BUD Total Dose 800ug</title>
          <description>The first intervention is BUD total dose 800ug, then Symbicort® total dose 800ug/24ug, then Formoterol (FORM) total dose 24ug, then Symbicort® total dose 400ug/12ug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">Study started in 2012/2013</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">Study completed</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort®, Formoterol, Budesonide</title>
          <description>All Patients will receive randomly one-off dose of the following treatments:&#xD;
Formoterol (FORM) total dose 24ug: is a LABA chosen at a higher clinical dose to determine whether this treatment can achieve an effective treatment response on GR in sputum cells compare to treatments 2 and 3.&#xD;
Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug) at a lower-dose to determine whether this combination can have an effect on GR in sputum cells compare to treatment 4, 1 and 3.&#xD;
Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose, chosen to compare the effect on GR with treatment 4 and 1&#xD;
BUD total dose 800ug: is an intermediate dose of ICS chosen for comparison with treatments 2 and 3 on GR.&#xD;
Symbicort®, Formoterol, Budesonide: Formeterol is Long acting beta 2-agonist (LABA) whereas Budesonide is inhaled corticosteroids (ICS).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator FEV1 (% pred.)</title>
          <units>% pred.</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="55" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator FVC (% pred.)</title>
          <units>% pred.</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93" lower_limit="83" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sputum CXCL8</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.4" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>GR-GRE Binding (Relative to Baseline)</title>
        <description>Enzyme immunosorbent assay system</description>
        <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
        <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (FORM) Total Dose 24ug</title>
            <description>Participants received Formoterol (FORM) total dose 24ug</description>
          </group>
          <group group_id="O2">
            <title>Symbicort® Total Dose 400ug/12ug</title>
            <description>Participants received 2 puffs of a combination of formoterol (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort® Total Dose 800ug/24ug</title>
            <description>Participants received 2 puffs of a combination of formoterol (12ug) and budesonide (400ug)</description>
          </group>
          <group group_id="O4">
            <title>Pulmicort 800ug</title>
            <description>Participants received 2 puffs of Budesoinde 400g (total dose 800ug)</description>
          </group>
        </group_list>
        <measure>
          <title>GR-GRE Binding (Relative to Baseline)</title>
          <description>Enzyme immunosorbent assay system</description>
          <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
          <units>Fold activation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                    <measurement group_id="O2" value="1.8" spread="0.1"/>
                    <measurement group_id="O3" value="2.3" spread="0.4"/>
                    <measurement group_id="O4" value="2.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in IL-6 Levels</title>
        <description>Changes in IL-6 Levels in the sputum supernatant compared to screening visit</description>
        <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
        <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (FORM) Total Dose 24ug</title>
            <description>2 puffs of Formoterol (FORM) 12ug (total dose 24ug)</description>
          </group>
          <group group_id="O2">
            <title>Symbicort® Total Dose 400ug/12ug</title>
            <description>2 puffs of a combination of formoterol (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort® Total Dose 800ug/24ug</title>
            <description>2 puffs of a combination of Formoterol (12ug) and budesonide (400ug)</description>
          </group>
          <group group_id="O4">
            <title>Pulmicort 800</title>
            <description>2 puffs of budesonide 400ug (total dose 800ug)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in IL-6 Levels</title>
          <description>Changes in IL-6 Levels in the sputum supernatant compared to screening visit</description>
          <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29" spread="25"/>
                    <measurement group_id="O2" value="-14" spread="19"/>
                    <measurement group_id="O3" value="-28" spread="22"/>
                    <measurement group_id="O4" value="-29" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CXCL8 Levels</title>
        <description>Changes in CXCL8 concentrations in sputum compared to screening visit.</description>
        <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
        <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (FORM) Total Dose 24ug</title>
            <description>2 puffs of Formoterol (FORM) 12ug (total dose 24ug)</description>
          </group>
          <group group_id="O2">
            <title>Symbicort® Total Dose 400ug/12ug</title>
            <description>2 puffs of a combination of Formoterol (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort® Total Dose 800ug/24ug</title>
            <description>2 puffs of a combination of Formoterol (12ug) and budesonide (400ug)</description>
          </group>
          <group group_id="O4">
            <title>Pulmicort 800</title>
            <description>budesonide total dose 800ug</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CXCL8 Levels</title>
          <description>Changes in CXCL8 concentrations in sputum compared to screening visit.</description>
          <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.35"/>
                    <measurement group_id="O2" value="-2.1" spread="0.7"/>
                    <measurement group_id="O3" value="-2.2" spread="0.55"/>
                    <measurement group_id="O4" value="-1.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in TNF Alpha</title>
        <description>Sputum TNF-alpha levels obtained from induced sputum compared to screening visit.</description>
        <time_frame>Screening visit and 2 hours post inhalation of treatment</time_frame>
        <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (FORM) Total Dose 24ug</title>
            <description>2 puffs of Formoterol (FORM) 12ug (total dose 24ug)</description>
          </group>
          <group group_id="O2">
            <title>Symbicort® Total Dose 400ug/12ug</title>
            <description>2 puffs of a combination of formoterol (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort® Total Dose 800ug/24ug</title>
            <description>2 puffs of a combination of formoterol (12ug) and BUD (400ug)</description>
          </group>
          <group group_id="O4">
            <title>Pulmicort 800ug</title>
            <description>budesonide total dose 800ug</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in TNF Alpha</title>
          <description>Sputum TNF-alpha levels obtained from induced sputum compared to screening visit.</description>
          <population>Low patient numbers due to the fact that only a small number of patients were able to produce sputum that was of sufficient quality to undertake analysis, furthermore, sputum production between patient visits was highly variable.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="9.0"/>
                    <measurement group_id="O2" value="-5.7" spread="7.9"/>
                    <measurement group_id="O3" value="-7.8" spread="7.3"/>
                    <measurement group_id="O4" value="-9.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lung Function Parameter FEV1</title>
        <description>Improvement in FEV1 compared to baseline levels.</description>
        <time_frame>Baseline and 2 hours post inhalation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Formoterol (FORM) Total Dose 24ug</title>
            <description>2 puffs of Formoterol (FORM) 12ug (total dose 24ug)</description>
          </group>
          <group group_id="O2">
            <title>Symbicort® Total Dose 400ug/12ug</title>
            <description>2 puffs of a combination of formoterol (6ug) and ICS (Budesonide, (BUD) 200ug)</description>
          </group>
          <group group_id="O3">
            <title>Symbicort® Total Dose 800ug/24ug:</title>
            <description>2 puffs of a combination of formoterol (12ug) and BUD (400ug)</description>
          </group>
          <group group_id="O4">
            <title>Pulmicort 800ug</title>
            <description>Budesonide total dose 800ug</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lung Function Parameter FEV1</title>
          <description>Improvement in FEV1 compared to baseline levels.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="28"/>
                    <measurement group_id="O2" value="120" spread="25"/>
                    <measurement group_id="O3" value="200" spread="30"/>
                    <measurement group_id="O4" value="52" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>All Adverse Events during the clinical investigation will be recorded and documented in the relevant section of the Case Report Form</desc>
      <group_list>
        <group group_id="E1">
          <title>Formoterol 24ug</title>
          <description>Formoterol (FORM) total dose 24ug:</description>
        </group>
        <group group_id="E2">
          <title>Symbicort® Total Dose 400ug/12ug:</title>
          <description>Symbicort® total dose 400ug/12ug: 2 puffs of combination formoterol (12ug) and BUD (200ug)</description>
        </group>
        <group group_id="E3">
          <title>Symbicort® Total Dose 800ug/24ug</title>
          <description>Symbicort® total dose 800ug/24ug: 2 puffs of a combination of formoterol (12ug) and BUD (400ug)</description>
        </group>
        <group group_id="E4">
          <title>Pulmicort 800ug</title>
          <description>budesonide total dose 800ug:</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Omar S Usmani</name_or_title>
      <organization>Imperial College</organization>
      <phone>+44 (0)20 7351 8051</phone>
      <email>o.usmani@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

